0.79

3.66% -0.03

After Hours: .83 0.04 +5.06%

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is traded at $0.79, with a volume of 44,337. It is down -3.66% in the last 24 hours and up +3.72% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Previous Close:

$0.82

Open:

$0.806

24h Volume:

44,337

Relative Volume:

0.01

Market Cap:

$18.24M

Revenue:

Net Income/Loss:

$-16.28M

P/E Ratio:

-0.0568

EPS:

-13.91

Net Cash Flow:

$-13.75M

1W Performance:

-5.69%

1M Performance:

+3.72%

6M Performance:

-0.03%

1Y Performance:

-37.30%

1-Day Range:

$0.79

$0.8375

1-Week Range:

$0.75

$0.8816

52-Week Range:

$0.281

$3.79

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(702) 514-4174

Address

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2024-08-11

Latest SEC Filings

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTTA Pasithea Therapeutics Corp	0.79	18.93M	0	-16.28M	-13.75M	-13.91
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Mar 03, 2026

Earnings Recap: Whats the beta of Pasithea Therapeutics Corp stockMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn

Mar 03, 2026

Fed Watch: Whats the beta of Pasithea Therapeutics Corp Equity Warrant stockIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn

Mar 03, 2026

Mar 02, 2026

Certain Options of Pasithea Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 3-MAR-2026. - marketscreener.com

Mar 02, 2026

Feb 28, 2026

KTTA PE Ratio & Valuation, Is KTTA Overvalued - Intellectia AI

Feb 28, 2026

KTTA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Coastlands entities hold 2.39M shares in Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan

Feb 27, 2026

Feb 26, 2026

KTTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 26, 2026

Feb 25, 2026

Breakout Move: Is Pasithea Therapeutics Corp Equity Warrant impacted by rising ratesPortfolio Return Summary & Comprehensive Market Scan Reports - baoquankhu1.vn

Feb 25, 2026

Feb 20, 2026

What’s next for Pasithea Therapeutics Corp. stockTrade Entry Report & AI Enhanced Execution Alerts - mfd.ru

Feb 20, 2026

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice - TipRanks

Feb 20, 2026

Pasithea Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Feb 20, 2026

Feb 17, 2026

CVI and Heights disclose 3.8% Pasithea (KTTA) stake via warrant holdings - Stock Titan

Feb 17, 2026

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network

Feb 17, 2026

Pasithea Therapeutics Corp. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative

Feb 17, 2026

Ameriprise discloses 8.4% Pasithea Therapeutics (NASDAQ: KTTA) stake - Stock Titan

Feb 17, 2026

Feb 15, 2026

Can Pasithea Therapeutics Corp. disrupt its industryQuarterly Market Summary & Daily Stock Trend Reports - mfd.ru

Feb 15, 2026

Feb 14, 2026

KTTA Should I Buy - Intellectia AI

Feb 14, 2026

Feb 12, 2026

Published on: 2026-02-12 18:27:19 - mfd.ru

Feb 12, 2026

Aug Mood: How does Pasithea Therapeutics Corp. correlate with NasdaqJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru

Feb 12, 2026

Feb 11, 2026

Published on: 2026-02-12 00:18:47 - mfd.ru

Feb 11, 2026

Why Pasithea Therapeutics Corp. stock is seen as undervaluedTrade Analysis Summary & AI Forecast for Swing Trade Picks - mfd.ru

Feb 11, 2026

What’s the beta of Pasithea Therapeutics Corp. stockWeekly Trading Summary & Precise Buy Zone Identification - mfd.ru

Feb 11, 2026

Why Pasithea Therapeutics Corp. Equity Warrant stock could be next big winnerJuly 2025 Price Swings & Daily Market Momentum Tracking - mfd.ru

Feb 11, 2026

Feb 10, 2026

Earnings Miss: Is Pasithea Therapeutics Corp Equity Warrant stock overvalued or fairly pricedJuly 2025 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn

Feb 10, 2026

Feb 08, 2026

Dividend Watch: What is the Moat Score of Pasithea Therapeutics Corp Equity WarrantGDP Growth & Stock Market Timing Techniques - baoquankhu1.vn

Feb 08, 2026

Feb 06, 2026